Literature DB >> 17620868

Therapy and clinical trials.

Ishwarlal Jialal, Sridevi Devaraj.   

Abstract

Mesh:

Substances:

Year:  2007        PMID: 17620868      PMCID: PMC2677957          DOI: 10.1097/MOL.0b013e32823bcb39

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


× No keyword cloud information.
  4 in total

1.  Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents.

Authors:  Luisa Gilardini; Philip G McTernan; Andrea Girola; Nancy F da Silva; Luisella Alberti; Sudhesh Kumar; Cecilia Invitti
Journal:  Atherosclerosis       Date:  2006-01-25       Impact factor: 5.162

2.  Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.

Authors:  Eugenia Negredo; José Moltó; Jordi Puig; Denise Cinquegrana; Anna Bonjoch; Núria Pérez-Alvarez; Raquel López-Blázquez; Asunción Blanco; Bonaventura Clotet; Celestino Rey-Joly
Journal:  AIDS       Date:  2006-11-14       Impact factor: 4.177

3.  Prevalence of metabolic syndrome after acute coronary syndrome and its prognostic significance.

Authors:  Carine Boulon; Marianne Lafitte; Vincent Richeboeuf; Bertrand Paviot; Vincent Pradeau; Pierre Coste; Jacques Bonnet; Thierry Couffinhal
Journal:  Am J Cardiol       Date:  2006-10-04       Impact factor: 2.778

4.  Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.

Authors:  Ronald B Goldberg; John R Guyton; Theodore Mazzone; Ruth S Weinstock; Adam Polis; Patricia Edwards; Joanne E Tomassini; Andrew M Tershakovec
Journal:  Mayo Clin Proc       Date:  2006-12       Impact factor: 7.616

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.